| Code | CSB-MP008645HU1(F3) |
| Abbreviation | Recombinant Human FGFR2 protein, partial (Active) |
| MSDS | |
| Size | $138 |
| Order now | |
| Image |
|
| Have Questions? | Leave a Message or Start an on-line Chat |
FGFR2 dysregulation drives oncogenesis in gastric, breast, and endometrial cancers, making this receptor a critical target for therapeutic intervention and biomarker discovery. This mammalian-expressed construct spanning residues 152–378 of isoform 3 captures the extracellular ligand-binding domain with native post-translational modifications that preserve conformational epitopes essential for antibody recognition. Functional ELISA validation demonstrates specific binding to an anti-FGFR2 recombinant antibody with an EC50 of 1.066–1.203 ng/mL, confirming that this protein supports competitive inhibition assays, blocking antibody screening, and therapeutic antibody epitope mapping in oncology drug discovery programs. The combination of >95% purity and <1.0 EU/μg endotoxin meets the quality thresholds commonly required for surface plasmon resonance affinity characterization, biolayer interferometry kinetic studies, and high-throughput small-molecule inhibitor screening where low background interference is critical for accurate KD determination.
There are currently no reviews for this product.